Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2007-02-20
2007-02-20
Chernyshev, Olga N. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S133100, C424S141100, C424S142100, C424S145100, C424S158100, C514S002600, C514S012200, C530S387100, C530S388100, C530S388150, C530S388240
Reexamination Certificate
active
09899815
ABSTRACT:
A method for the treatment of Alzheimer's disease in a subject having or suspected of having Alzheimer's disease by administering to the subject a therapeutically effective amount of an antibody wherein the antibody is raised against a protofibril that contains an Aβ-Arc peptide.
REFERENCES:
patent: 5854204 (1998-12-01), Findeis et al.
patent: WO 9511994 (1995-05-01), None
patent: WO 9531996 (1995-11-01), None
patent: WO 9927944 (1999-06-01), None
patent: WO 0039310 (2000-07-01), None
patent: WO 0072876 (2000-12-01), None
Vickers, 2002, Drugs Aging, 19(7), pp. 487-494.
Schenk, et al., Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP, Letters to Nature, 400:173-177 (Jul. 8, 1999).
St. George-Hyslop, et al., Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder, Letters to Nature, 347:194-197 (Sep. 13, 1990).
Wirak, et al., Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice, Science, 253:323-325 (Jul. 19, 1991).
St. George-Hyslop, et al., The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21, Science, 235:885-890 (Feb. 20, 1987).
Walsh, et al., Amyloid β-Protein Fibrillogenesis, The Journal of Biological Chemistry, 272(35):22364-22372 (Aug. 29, 1997).
Weidemann, et al., Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein, Cell 57:115-126 (Apr. 7, 1989).
Giulian, et al., The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease, The Journal of Biological Chemistry, 273(45):29719-29726 (Nov. 6, 1998).
Palmert, et al., The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci. USA, 86:6338-6342 (Aug. 1989).
Levy, et al., Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type, Science, 248:1124-1126 (Jun. 1, 1990).
Conway, et al., Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy, PNAS, 97(2):571-576 (Jan. 18, 2000).
Mullan, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid, Nature Genetics, 1:345-347 (Aug. 1992).
Hendriks, et al., Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene, Nature Genetics, 1:218-221 (Jun. 1992).
De Jonghe, et al., Flemish and Dutch Mutations in Amyloid β Precursor Protein Have Different Effects on Amyloid β Secretion, Neurobiology of Disease, 5:281-286 (accepted for publ., Aug. 19, 1998).
Kamino, et al., Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Region, Am. J. Hum. Genet. 51:998-1014 (revision recieved Jul. 24, 1992).
Citron, et al., Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice, Nature Medicine, 3(1):67-72 (Jan. 1997).
Forsell, et al., Amyloid precursor protein mutation at codon 713 (Ala—Val) does not cause schizophrenia: non-pathogenic variant found at codon 705 (silent), Neuroscience Letters, 184:90-93 (accepted Nov. 18, 1994).
Hardy, Amyloid, the presenilins and Alzheimer's disease, Trends Neurosci., 20(4):154-159 (1997).
Grabowski, et al., Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy, Ann. Neurol., 49:697-705 (published online Mar. 19, 2001).
Scheuner, et al., Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increasedIn vivoby the presenilin 1 and 2 andAPPmutations linked to familial Alzheimer's disease, Nature Medicine, 2(8):864-870 (Aug. 1996).
Serpell, Alzheimer's amyloid fibrils: structure and assembly, Biochimica et Biophysica Acta, 1502:16-30 (accepted Nov. 24, 1999).
Harper, et al., Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease, Biochemistry, 38:8972-8980 (published online Jun. 18, 1999).
Bacskai, et al., Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nature Medicine, 7(3):369-372 (Mar. 2001).
Frenkel, et al., Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000).
Bard, et al., Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000).
Morgan, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000).
Janus, et al., Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000).
Chen, et al., A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978 (Dec. 2000).
Nilsberth, et al.,A Novel APP Muatation(E693G)—The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms,Society for Neuiroscience Annual Meeting, Miami Beach, Abstract, Nov. 1999.
Lannfelt Lars
Näslund Jan
Nilsberth Camilla
Westlind-Danielsson Anita
Chernyshev Olga N.
Lannfelt Lars
Young & Thompson
LandOfFree
Treatment of alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876934